Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Arreola-Guerra JM, Serrano M, Morales-Buenrostro LE, Vilatobá M, Alberú J. Tacrolimus trough levels as a risk factor for acute rejection in renal transplant patients. Ann. Transplant 21, 105–114 (2016).
  Medline CASGoogle Scholar
• 2 Egeland EJ, Robertsen I, Hermann M et al. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation 101(8), e273–e279 (2017).
  Medline CASGoogle Scholar
• 3 Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc. 30(4), 1355–1358 (1998).
  Medline CASGoogle Scholar
• 4 Jacobson PA, Oetting WS, Brearley AM et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 91(3), 300–308 (2011).
  Medline CASGoogle Scholar
• 5 Israni AK, Riad SM, Leduc R et al. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF genomics. Transpl. Int. 26(10), 982–989 (2013).
  Medline CASGoogle Scholar
• 6 Chen D, Guo F, Shi J et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. Drug Metab. Pharmacokinet. 29(3), 249–253 (2014).
  Medline CASGoogle Scholar
• 7 Li CJ, Li L, Lin L et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS ONE 9(1), e86206 (2014).
  MedlineGoogle Scholar
• 8 Zhang X, Wang Z, Fan J, Liu G, Peng Z. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur. J. Clin. Pharmacology 67(8), 803–813 (2011).
  Medline CASGoogle Scholar
• 9 Li D, Zhu JY, Wang X, Lou YQ, Zhang GL. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin. Chim. Acta. 383(1–2), 133–139 (2007).
  Medline CASGoogle Scholar
• 10 Liu MZ, He HY, Zhang YL et al. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients. Acta Pharmacol. Sin. 23, 38(3), 415–423 (2017).
  Medline CASGoogle Scholar
• 11 Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H. A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET^™ Plus platform. Pharmacogenomics J. 17(2), 174–179 (2016).
  MedlineGoogle Scholar
• 12 Li JI, Liu S, Fu Q et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics 16(12), 1355–1365 (2015).
  CASGoogle Scholar
• 13 Press RR, Ploeger BA, den Hartigh J et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther. Drug Monit. 31(2), 187–197 (2009).
  Medline CASGoogle Scholar
• 14 Barraclough KA, Isbel NM, Lee KJ et al. NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation 94(10), 1025–1032 (2012).
  Medline CASGoogle Scholar
• 15 Chen D, Fan J, Guo F, Qin S, Wang Z, Peng Z. Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients. PLoS ONE 8(8), e73405 (2013).
  Medline CASGoogle Scholar
• 16 Elens L, Hesselink DA, Bouamar R et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther. Drug Monit. 36(1), 71–79 (2014).
  Medline CASGoogle Scholar
• 17 Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 53(2), 123–139 (2014).
  Medline CASGoogle Scholar
• 18 Lesche D, Sigurdardottir V, Setoud R et al. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Ther. Drug Monit. 36(6), 710–715 (2014).
  Medline CASGoogle Scholar
• 19 Lunde I, Bremer S, Midtvedt K et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur. J. Clin. Pharmacol. 70(6), 685–693 (2014).
  Medline CASGoogle Scholar
• 20 Tang JT, Andrews LM, van Gelder T et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin. Drug Metab. Toxicol. 12(5), 555–565 (2016).
  Medline CASGoogle Scholar
• 21 Kuypers DR, de Loor H, Naesens M, Coopmans T, de Jonge H. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenet. Genomics. 24(12), 597–606 (2014).
  Medline CASGoogle Scholar
• 22 Jannot AS, Vuillemin X, Etienne I et al. A lack of significant effect of POR*28 allelic variant on tacrolimus exposure in kidney transplant recipients. Ther. Drug Monit. 38(2), 223–229 (2016).
  Medline CASGoogle Scholar
• 23 Yan L, Li Y, Tang JT, An YF, Wang LL, Shi YY. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Pharmacogenomics 17(3), 249–257 (2016).
  CASGoogle Scholar
• 24 Ruiz J, Herrero MJ, Bosó V et al. Impact of single nucleotide polymorphisms (SNPs) on immunosuppressive therapy in lung transplantation. Int. J. Mol. Sci. 16(9), 20168–20182 (2015).
  Medline CASGoogle Scholar
• 25 Naito T, Mino Y, Aoki Y et al. ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Clin. Chim. Acta. 445, 79–84 (2015).
  Medline CASGoogle Scholar
• 26 Knops N, van den Heuvel LP, Masereeuw R et al. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. Mol. Pharm. 12(3), 758–768 (2015).
  Medline CASGoogle Scholar
• 27 Kravljaca M, Perovic V, Pravica V et al. The importance of MDR1 gene polymorphisms for tacrolimus dosage. Eur. J. Pharm. Sci. 83, 109–113 (2016).
  Medline CASGoogle Scholar
• 28 Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br. J. Clin. Pharmacol. 78(2), 364–372 (2014).
  Medline CASGoogle Scholar
• 29 Genvigir FD, Salgado PC, Felipe CR et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet. Genomics 26(10), 462–472 (2016).
  Medline CASGoogle Scholar
• 30 Elens L, Capron A, Kerckhove VV et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 17(10), 873–883 (2007).
  Medline CASGoogle Scholar
• 31 Dessilly G, Elens L, Panin N et al. ABCB1 1199G>A genetic polymorphism (rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS ONE 9(3), e91555 (2014).
  MedlineGoogle Scholar
• 32 Oetting WS, Schladt DP, Guan W et al. Genome wide association study of tacrolimus concentrations in African–American kidney transplant recipients identifies multiple CYP3A5 ALLELES. Am. J. Transplant. 16(2), 574–582 (2016).
  Medline CASGoogle Scholar
• 33 Santoro A, Felipe CR, Tedesco-Silva H et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12(9), 1293–1303 (2011).
  CASGoogle Scholar
• 34 Onizuka M, Kunii N, Toyosaki M et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 46, 1113–1117 (2011).
  Medline CASGoogle Scholar
• 35 Mac Guad R, Zaharan NL, Chik Z, Mohamed Z, Peng NK, Adnan WA. Effects of CYP3A5 genetic polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 48(1), 81–87 (2016).
  Medline CASGoogle Scholar
• 36 Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Exp. Clin. Transplant (Suppl. 1), 197–200 (2015).
  MedlineGoogle Scholar
• 37 Khaled SK, Palmer JM, Herzog J et al. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 22(2), 268–276 (2016).
  Medline CASGoogle Scholar
• 38 Fan J, Zhang X, Ren L et al. Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies. Pharmacogenomics 16(3), 239–250 (2015).
  CASGoogle Scholar
• 39 de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J. 15(2), 144–152 (2015).
  Medline CASGoogle Scholar
• 40 Iwamoto T, Monma F, Fujieda A et al. Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation. Ther. Drug Monit. 37(5), 581–588 (2015).
  Medline CASGoogle Scholar
• 41 Xing J, Zhang X, Fan J, Shen B, Men T, Wang J. Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients. Eur. J. Clin. Pharmacol. 71(2), 191–198 (2015).
  Medline CASGoogle Scholar
• 42 Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin. Pharmacokinet. 52(9), 751–762 (2013).
  Medline CASGoogle Scholar
• 43 Li DY, Teng RC, Zhu HJ, Fang Y. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int. J. Clin. Pharmacol. Ther. 51(6), 466–474 (2013).
  Medline CASGoogle Scholar
• 44 Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J. Clin. Pharm. Ther. 36(5), 614–624 (2011).
  Medline CASGoogle Scholar
• 45 Kurzawski M, Dąbrowska J, Dziewanowski K, Domański L, Perużyńska M, Droździk M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 15(2), 179–188 (2014).
  CASGoogle Scholar
• 46 Bruckmueller H, Werk AN, Renders L et al. Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Ther. Drug Monit. 37(3), 288–295 (2015).
  Medline CASGoogle Scholar
• 47 Pallet N, Jannot AS, El Bahri M et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am. J. Transplant 15(3), 800–805 (2015).
  Medline CASGoogle Scholar
• 48 Aouam K, Kolsi A, Kerkeni E et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics 16(18), 2045–2054 (2015).
  CASGoogle Scholar
• 49 Shi WL, Tang HL, Zhai SD. Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS ONE 10(6), e0127995 (2015).
  MedlineGoogle Scholar
• 50 Yousef AM, Qosa H, Bulatova N et al. Effects of genetic polymorphism in CYP3A4 and CYP3A5 genes on tacrolimus dose among kidney transplant recipients. Iran J. Kidney Dis. 10(3), 156–163 (2016).
  MedlineGoogle Scholar
• 51 de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin. Pharmacol. Ther. 92(3), 366–375 (2012).
  Medline CASGoogle Scholar
• 52 Wang Z, Wu S, Chen D et al. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. Eur. J. Clin. Pharmacol. 70(8), 925–931 (2014).
  Medline CASGoogle Scholar
• 53 Bosó V, Herrero MJ, Bea S et al. Increased hospital stay and allograft dysfunction in renal transplant recipients with CYP2C19 AA variant in SNP rs4244285. Drug Metab. Dispos. 41(2), 480–487 (2013).
  Medline CASGoogle Scholar
• 54 Damon C, Luck M, Toullec L et al. predictive modeling of tacrolimus dose requirement based on high-throughput genetic screening. Am. J. Transplant. 17(4), 1008–1019 (2016).
  MedlineGoogle Scholar
• 55 Boivin AA, Cardinal H, Barama A et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab. Pharmacokinet. 28(3), 274–277 (2013).
  Medline CASGoogle Scholar
• 56 Jacobson PA, Oetting WS, Brearley AM et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 91(3), 300–308 (2011).
  Medline CASGoogle Scholar
• 57 Oetting WS, Jacobson PA, Israni AK. Validation is critical for GWAS-based associations. Am. J. Transplant 17(2), 318–319 (2017).
  Medline CASGoogle Scholar
• 58 Oetting WS, Wu B, Schladt DP et al. Genome wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. Pharmacogen. J. (2017) (Epub ahead of print).
  Google Scholar
• 59 Israni A, Leduc R, Holmes J et al. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 90(12), 1401–1408 (2010).
  Medline CASGoogle Scholar
• 60 Pulk RA, Schladt DS, Oetting WS et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics 16(8), 841–854 (2015).
  CASGoogle Scholar
• 61 Li YR, van Setten J, Verma SS et al. Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Med. 7, 90 (2015).
  MedlineGoogle Scholar
• 62 Johnson AD, Handsaker RE, Pulit S, Nizzari MM, O'Donnell CJ, de Bakker PI. W. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24(24), 2938–2939 (2008).
  Medline CASGoogle Scholar
• 63 Hewett M, Oliver DE, Rubin DL et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 30(1), 163–165 (2002).
  Medline CASGoogle Scholar